EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study

Yacheng Wang, Heng Zhang, Zibo Tang, Dehua Kang, Weihao Xie, Xiaoshi Zhang, Lixia Lu

Frontiers in Oncology · 02.04.2026 · 16

DOI: 10.3389/fonc.2026.1782102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 02.04.2026. Verfasst von Yacheng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Central Hospital of Wuhan, Key Laboratory for Molecular Diagnosis of Hubei Province, Tongji Medical College, Huazhong Uni…. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Melanoma brain metastasis (MBM) is associated with a poor prognosis and a high risk of intracranial hemorrhage (ICH), which may complicate the use of stereotactic radiosurgery (SRS). This study evaluated the efficacy and safety of hypofractionated radiotherapy (HFRT) for MBM, with a specific focus on metastases with hemorrhagic components. Patients and methods In this single-center retrospective study, 26 patients with MBMs received HRT regimens of 30 Gy/5 fractions, 36 Gy/6 fractions, or 42 Gy/7 fractions. The primary endpoint was the local control (LC) rate assessed on the first MRI evaluation after radiotherapy completion (1–3 months after radiotherapy completion). Secondary endpoints included intracranial progression-free survival (IPFS), overall survival (OS), and treatment-related adverse events (AEs).

Results

The disease control rate was 96% at the 3-month assessment (2 complete responses, 16 partial responses, 7 stable disease). The median OS was 10.5 months and the median IPFS was 4.5 months. No grade ≥3 AEs or symptomatic radiation necrosis occurred during the follow-up period (median 7.5 months). Notably, no radiotherapy-related ICH or exacerbation of pre-existing hemorrhage was observed, and hemorrhage reduction was achieved in all 11 patients with baseline ICH (100%).

Conclusion

HFRT demonstrated promising local control and a favorable safety profile in this cohort of MBM patients, It shows particular potential for treating hemorrhagic metastases and may offer a valuable alternative to SRS in selected high-risk scenarios, meriting further investigation in larger studies.

Schlagwörter

Stichwörter der Autor:innen

brain metastaseshypofractionated radiotherapyintracranial hemorrhagelocal controlmelanomasafety

Autor:innen und Institutionen

  • Department of Oncology, The Central Hospital of Wuhan, Key Laboratory for Molecular Diagnosis of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Oncology, Longgang District Central Hospital of Shenzhen, Shenzhen, Guangdong, China.
  • Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, Chi…
  • Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.

Zitieren

APA

Wang, Y., Zhang, H., Tang, Z., Kang, D., Xie, W., Zhang, X., & Lu, L. (2026). Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1782102

Vancouver

Wang Y, Zhang H, Tang Z, Kang D, Xie W, Zhang X, et al. Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1782102

BibTeX
@article{Wang2026,
  author = {Wang, Yacheng and Zhang, Heng and Tang, Zibo and Kang, Dehua and Xie, Weihao and Zhang, Xiaoshi and Lu, Lixia},
  title = {Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1782102}
}
Kostenlos starten →